AXSM
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Axsome presented results from the Shared Goals survey of caregivers of patients with Alzheimer’s disease agitation at Psych Congress 2026Sep 21, 2026
- Axsome Therapeutics initiated the SUMMIT Phase 3 trial of AXS-05 for smoking cessationAug 31, 2026
- FDA accepted Axsome Therapeutics' NDA for AXS-12 to treat cataplexy in narcolepsyJul 15, 2026
- Axsome Therapeutics initiated the Phase 3 FOCUS-2 trial of solriamfetol in children with ADHDJul 8, 2026
- Axsome Therapeutics reached a settlement resolving all SUNOSI patent litigationJun 3, 2026